0001104659-21-037316.txt : 20210316
0001104659-21-037316.hdr.sgml : 20210316
20210316200121
ACCESSION NUMBER: 0001104659-21-037316
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210315
FILED AS OF DATE: 20210316
DATE AS OF CHANGE: 20210316
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BILINSKY IGOR
CENTRAL INDEX KEY: 0001594604
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36860
FILM NUMBER: 21747938
MAIL ADDRESS:
STREET 1: C/O VICAL INCORPORATED
STREET 2: 10390 PACIFIC CENTER COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001425205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 753254381
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 6502607120
MAIL ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: Lion Biotechnologies, Inc.
DATE OF NAME CHANGE: 20131015
FORMER COMPANY:
FORMER CONFORMED NAME: Genesis Biopharma, Inc
DATE OF NAME CHANGE: 20100319
FORMER COMPANY:
FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP
DATE OF NAME CHANGE: 20080128
4
1
tm219836d2_4.xml
OWNERSHIP DOCUMENT
X0306
4
2021-03-15
0
0001425205
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
0001594604
BILINSKY IGOR
C/O IOVANCE BIOTHERAPEUTICS, INC.
999 SKYWAY ROAD, SUITE 150
SAN CARLOS
CA
94070
0
1
0
0
Chief Operating Officer
Stock Option (right to buy)
34.91
2021-03-15
4
A
0
150000
0.00
A
2031-03-15
Common stock
150000
150000
D
Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
/s/ Igor Bilinsky
2021-03-16